These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 24265276)
1. The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cholewa BD; Liu X; Ahmad N Cancer Res; 2013 Dec; 73(23):6848-55. PubMed ID: 24265276 [TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass. Chun G; Bae D; Nickens K; O'Brien TJ; Patierno SR; Ceryak S Carcinogenesis; 2010 May; 31(5):785-93. PubMed ID: 20089605 [TBL] [Abstract][Full Text] [Related]
3. Ectopic expression of Plk1 leads to activation of the spindle checkpoint. Tang J; Erikson RL; Liu X Cell Cycle; 2006 Nov; 5(21):2484-8. PubMed ID: 17102638 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253 [TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883 [TBL] [Abstract][Full Text] [Related]
6. Getting in and out of mitosis with Polo-like kinase-1. van Vugt MA; Medema RH Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519 [TBL] [Abstract][Full Text] [Related]
7. Non-mitotic functions of polo-like kinases in cancer cells. Raab CA; Raab M; Becker S; Strebhardt K Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265 [TBL] [Abstract][Full Text] [Related]
8. The Plk1 Polo box domain mediates a cell cycle and DNA damage regulated interaction with Chk2. Tsvetkov LM; Tsekova RT; Xu X; Stern DF Cell Cycle; 2005 Apr; 4(4):609-17. PubMed ID: 15876876 [TBL] [Abstract][Full Text] [Related]
9. Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies. Wachowicz P; Fernández-Miranda G; Marugán C; Escobar B; de Cárcer G Bioessays; 2016 Jul; 38 Suppl 1():S96-S106. PubMed ID: 27417127 [TBL] [Abstract][Full Text] [Related]
10. PLK1 targets NOTCH1 during DNA damage and mitotic progression. De Blasio C; Zonfrilli A; Franchitto M; Mariano G; Cialfi S; Verma N; Checquolo S; Bellavia D; Palermo R; Benelli D; Screpanti I; Talora C J Biol Chem; 2019 Nov; 294(47):17941-17950. PubMed ID: 31597699 [TBL] [Abstract][Full Text] [Related]
11. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. Lasek AL; McPherson BM; Trueman NG; Burkard ME PLoS One; 2016; 11(2):e0150225. PubMed ID: 26919439 [TBL] [Abstract][Full Text] [Related]
12. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081 [No Abstract] [Full Text] [Related]
13. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Jang YJ; Kim YS; Kim WH Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274 [TBL] [Abstract][Full Text] [Related]
14. Plk1 overexpression induces chromosomal instability and suppresses tumor development. de Cárcer G; Venkateswaran SV; Salgueiro L; El Bakkali A; Somogyi K; Rowald K; Montañés P; Sanclemente M; Escobar B; de Martino A; McGranahan N; Malumbres M; Sotillo R Nat Commun; 2018 Aug; 9(1):3012. PubMed ID: 30069007 [TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. Studach LL; Rakotomalala L; Wang WH; Hullinger RL; Cairo S; Buendia MA; Andrisani OM Hepatology; 2009 Aug; 50(2):414-23. PubMed ID: 19472310 [TBL] [Abstract][Full Text] [Related]
16. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022 [TBL] [Abstract][Full Text] [Related]
17. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions. Bibi N; Parveen Z; Rashid S PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120 [TBL] [Abstract][Full Text] [Related]
18. Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1). Li Z; Lu Y; Ahmad N; Strebhardt K; Liu X Cell Cycle; 2015; 14(19):3030-9. PubMed ID: 26292025 [TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746 [TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Luo J; Liu X Protein Cell; 2012 Mar; 3(3):182-97. PubMed ID: 22447658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]